Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Fresh Tracks Therapeutics, Inc. (VICL) since 2014 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Fresh Tracks Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 819050.
Total stock buying since 2014: $2,448,920.
Total stock sales since 2014: $979,107.
Total stock option exercises since 2014: $0.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2024 | 902,681 | $839,289 | 0 | $0 | 0 | $0 |
| 2023 | 77,000 | $65,840 | 74 | $67 | 110,000 | $0 |
| 2021 | 360,101 | $297,124 | 0 | $0 | 85,000 | $0 |
| 2020 | 209,049 | $42,990 | 0 | $0 | 35,776 | $0 |
| 2019 | 0 | $0 | 2,190,500 | $644,007 | 0 | $0 |
| 2018 | 2,160,500 | $864,924 | 0 | $0 | 0 | $0 |
| 2017 | 85,700 | $149,975 | 19,192 | $43,755 | 0 | $0 |
| 2016 | 41,856 | $188,778 | 193,444 | $151,198 | 0 | $0 |
| 2015 | 0 | $0 | 83,642 | $73,814 | 0 | $0 |
| 2014 | 0 | $0 | 54,325 | $66,266 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2024-06 | 405,500 | $381,169 | 0 | $0 | 0 | $0 |
| 2024-05 | 250,216 | $230,131 | 0 | $0 | 0 | $0 |
| 2024-04 | 42,448 | $38,354 | 0 | $0 | 0 | $0 |
| 2024-03 | 54,517 | $49,067 | 0 | $0 | 0 | $0 |
| 2024-01 | 150,000 | $140,568 | 0 | $0 | 0 | $0 |
| 2023-12 | 77,000 | $65,840 | 74 | $67 | 0 | $0 |
| 2023-10 | 0 | $0 | 0 | $0 | 75,000 | $0 |
| 2023-09 | 0 | $0 | 0 | $0 | 35,000 | $0 |
| 2021-07 | 218,124 | $145,743 | 0 | $0 | 0 | $0 |
| 2021-05 | 41,977 | $33,581 | 0 | $0 | 0 | $0 |
| 2021-03 | 100,000 | $117,800 | 0 | $0 | 85,000 | $0 |
| 2020-09 | 52,526 | $42,990 | 0 | $0 | 0 | $0 |
| 2020-08 | 0 | $0 | 0 | $0 | 2,972 | $0 |
| 2020-07 | 0 | $0 | 0 | $0 | 2,969 | $0 |
| 2020-06 | 156,523 | $0 | 0 | $0 | 2,969 | $0 |
| 2020-05 | 0 | $0 | 0 | $0 | 2,969 | $0 |
| 2020-04 | 0 | $0 | 0 | $0 | 2,971 | $0 |
| 2020-03 | 0 | $0 | 0 | $0 | 2,968 | $0 |
| 2020-02 | 0 | $0 | 0 | $0 | 17,958 | $0 |
| 2019-01 | 0 | $0 | 2,190,500 | $644,007 | 0 | $0 |
| 2018-06 | 2,060,500 | $817,124 | 0 | $0 | 0 | $0 |
| 2018-01 | 100,000 | $47,800 | 0 | $0 | 0 | $0 |
| 2017-11 | 85,700 | $149,975 | 0 | $0 | 0 | $0 |
| 2017-03 | 0 | $0 | 5,125 | $11,260 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-06-10 | Exploration Capital, Llc | Buy | 86,185 | .94 | 81,013 |
| 2024-06-07 | Exploration Capital, Llc | Buy | 319,315 | .94 | 300,156 |
| 2024-05-31 | Exploration Capital, Llc | Buy | 516 | .89 | 459 |
| 2024-05-30 | Exploration Capital, Llc | Buy | 9,838 | .92 | 9,050 |
| 2024-05-29 | Exploration Capital, Llc | Buy | 80 | .87 | 69 |
| 2024-05-20 | Exploration Capital, Llc | Buy | 797 | .91 | 725 |
| 2024-05-16 | Exploration Capital, Llc | Buy | 73,768 | .92 | 67,866 |
| 2024-05-06 | Exploration Capital, Llc | Buy | 320 | .89 | 284 |
| 2024-05-03 | Exploration Capital, Llc | Buy | 324 | .91 | 294 |
| 2024-05-02 | Exploration Capital, Llc | Buy | 2,222 | .91 | 2,022 |
| 2024-05-01 | Exploration Capital, Llc | Buy | 162,351 | .92 | 149,362 |
| 2024-04-23 | Exploration Capital, Llc | Buy | 343 | .91 | 312 |
| 2024-04-22 | Exploration Capital, Llc | Buy | 16,908 | .90 | 15,217 |
| 2024-04-19 | Exploration Capital, Llc | Buy | 4,277 | .91 | 3,892 |
| 2024-04-10 | Exploration Capital, Llc | Buy | 1,000 | .88 | 880 |
| 2024-04-09 | Exploration Capital, Llc | Buy | 2,188 | .88 | 1,925 |
| 2024-04-05 | Exploration Capital, Llc | Buy | 1,050 | .91 | 955 |
| 2024-04-04 | Exploration Capital, Llc | Buy | 3,400 | .91 | 3,094 |
| 2024-04-03 | Exploration Capital, Llc | Buy | 12,928 | .91 | 11,764 |
| 2024-04-01 | Exploration Capital, Llc | Buy | 354 | .89 | 315 |
| 2024-03-28 | Exploration Capital, Llc | Buy | 2,586 | .90 | 2,327 |
| 2024-03-27 | Exploration Capital, Llc | Buy | 51,634 | .90 | 46,470 |
| 2024-03-20 | Exploration Capital, Llc | Buy | 287 | .91 | 261 |
| 2024-03-19 | Exploration Capital, Llc | Buy | 10 | .90 | 9 |
| 2024-01-17 | Exploration Capital, Llc | Buy | 9,038 | .99 | 8,947 |
| 2024-01-12 | Exploration Capital, Llc | Buy | 10,958 | .98 | 10,738 |
| 2024-01-11 | Exploration Capital, Llc | Buy | 3,839 | .98 | 3,762 |
| 2024-01-10 | Exploration Capital, Llc | Buy | 9,646 | .98 | 9,453 |
| 2024-01-09 | Exploration Capital, Llc | Buy | 38,017 | .98 | 37,256 |
| 2024-01-04 | Exploration Capital, Llc | Buy | 54,625 | .90 | 49,162 |
| 2024-01-03 | Exploration Capital, Llc | Buy | 23,877 | .89 | 21,250 |
| 2023-12-20 | Exploration Capital, Llc | Buy | 47,000 | .84 | 39,480 |
| 2023-12-08 | Fox-collis Aaron (VP of Finance & CAO) | Sale | 74 | .91 | 67 |
| 2023-12-06 | Exploration Capital General Partner, Llc | Buy | 17,233 | .90 | 15,509 |
| 2023-12-05 | Exploration Capital General Partner, Llc | Buy | 5,188 | .85 | 4,409 |
| 2023-12-04 | Exploration Capital General Partner, Llc | Buy | 7,579 | .85 | 6,442 |
| 2023-10-02 | Sklawer Andrew D (President and CEO) | Option Ex | 55,000 | .00 | 0 |
| 2023-10-02 | Mcavoy David R. (Gen Counsel, CCO, & Secretary) | Option Ex | 20,000 | .00 | 0 |
| 2023-09-01 | Chadha Deepak (Former Chief R&D Officer & COO) | Option Ex | 35,000 | .00 | 0 |
| 2021-07-26 | Hardy Reginald L (CHAIRMAN OF THE BOARD) | Buy | 100,000 | .67 | 67,400 |
| 2021-07-23 | Mcavoy David R. (General Counsel and CCO) | Buy | 18,124 | .67 | 12,143 |
| 2021-07-23 | Hardy Reginald L (CHAIRMAN OF THE BOARD) | Buy | 100,000 | .66 | 66,200 |
| 2021-05-17 | Sklawer Andrew D (COO and Secretary) | Buy | 15,375 | .80 | 12,300 |
| 2021-05-17 | Mcavoy David R. (General Counsel and CCO) | Buy | 26,602 | .80 | 21,281 |
| 2021-03-16 | Chadha Deepak (Chief Research & Dev. Officer) | Option Ex | 25,000 | .00 | 0 |
| 2021-03-16 | Breton Jose (Chief Accounting Officer) | Option Ex | 15,000 | .00 | 0 |
| 2021-03-16 | Sklawer Andrew D (COO and Secretary) | Option Ex | 20,000 | .00 | 0 |
| 2021-03-16 | Mcavoy David R. (General Counsel and CCO) | Option Ex | 25,000 | .00 | 0 |
| 2021-03-15 | Brown Robert Busard (Chief Executive Officer) | Buy | 100,000 | 1.18 | 117,800 |
| 2020-09-18 | Mcavoy David R. (General Counsel and CCO) | Buy | 22,526 | .83 | 18,809 |
| 2020-09-16 | Veru Dennison T (Director) | Buy | 14,645 | .80 | 11,759 |
| 2020-09-15 | Veru Dennison T (Director) | Buy | 15,355 | .81 | 12,422 |
| 2020-08-31 | Veru Dennison T (Director) | Option Ex | 788 | .00 | 0 |
| 2020-08-31 | Samant Vijay B (Director) | Option Ex | 609 | .00 | 0 |
| 2020-08-31 | Lyons Gary A (Director) | Option Ex | 692 | .00 | 0 |
| 2020-08-31 | Hardy Reginald L (Chairman of the Board) | Option Ex | 883 | .00 | 0 |
| 2020-07-31 | Veru Dennison T (Director) | Option Ex | 787 | .00 | 0 |
| 2020-07-31 | Samant Vijay B (Director) | Option Ex | 608 | .00 | 0 |
| 2020-07-31 | Lyons Gary A (Director) | Option Ex | 692 | .00 | 0 |
| 2020-07-31 | Hardy Reginald L (Chairman of the Board) | Option Ex | 882 | .00 | 0 |
| 2020-06-30 | Veru Dennison T | Option Ex | 787 | .00 | 0 |
| 2020-06-30 | Samant Vijay B | Option Ex | 608 | .00 | 0 |
| 2020-06-30 | Lyons Gary A | Option Ex | 691 | .00 | 0 |
| 2020-06-30 | Hardy Reginald L (Chairman of the Board) | Option Ex | 883 | .00 | 0 |
| 2020-06-22 | Chadha Deepak (Chief Research & Dev. Officer) | Buy | 26,087 | .00 | 0 |
| 2020-06-22 | Brown Robert Busard (Chief Executive Officer) | Buy | 86,957 | .00 | 0 |
| 2020-06-22 | Sklawer Andrew D (COO and Secretary) | Buy | 13,044 | .00 | 0 |
| 2020-06-22 | Mcavoy David R. (General Counsel and CCO) | Buy | 30,435 | .00 | 0 |
| 2020-05-31 | Veru Dennison T (Director) | Option Ex | 787 | .00 | 0 |
| 2020-05-31 | Samant Vijay B (Director) | Option Ex | 608 | .00 | 0 |
| 2020-05-31 | Lyons Gary A (Director) | Option Ex | 692 | .00 | 0 |
| 2020-05-31 | Hardy Reginald L (Chairman of the Board) | Option Ex | 882 | .00 | 0 |
| 2020-04-30 | Veru Dennison T (Director) | Option Ex | 787 | .00 | 0 |
| 2020-04-30 | Samant Vijay B (Director) | Option Ex | 609 | .00 | 0 |
| 2020-04-30 | Lyons Gary A (Director) | Option Ex | 692 | .00 | 0 |
| 2020-04-30 | Hardy Reginald L (Chairman of the Board) | Option Ex | 883 | .00 | 0 |
| 2020-03-31 | Veru Dennison T (Director) | Option Ex | 787 | .00 | 0 |
| 2020-03-31 | Samant Vijay B (Director) | Option Ex | 608 | .00 | 0 |
| 2020-03-31 | Lyons Gary A (Director) | Option Ex | 691 | .00 | 0 |
| 2020-03-31 | Hardy Reginald L (Chairman of the Board) | Option Ex | 882 | .00 | 0 |
| 2020-02-29 | Veru Dennison T (Director) | Option Ex | 787 | .00 | 0 |
| 2020-02-29 | Samant Vijay B (Director) | Option Ex | 608 | .00 | 0 |
| 2020-02-29 | Lyons Gary A (Director) | Option Ex | 692 | .00 | 0 |
| 2020-02-29 | Hardy Reginald L (Chairman of the Board) | Option Ex | 883 | .00 | 0 |
| 2020-02-14 | Veru Dennison T (Director) | Option Ex | 3,973 | .00 | 0 |
| 2020-02-14 | Samant Vijay B (Director) | Option Ex | 3,070 | .00 | 0 |
| 2020-02-14 | Lyons Gary A (Director) | Option Ex | 3,491 | .00 | 0 |
| 2020-02-14 | Hardy Reginald L (Chairman of the Board) | Option Ex | 4,454 | .00 | 0 |
| 2019-01-10 | Boyd Steven | Sale | 2,190,500 | .29 | 644,007 |
| 2018-06-28 | Boyd Steven | Buy | 1,276,591 | .40 | 513,189 |
| 2018-06-27 | Boyd Steven | Buy | 32,030 | .41 | 13,100 |
| 2018-06-26 | Boyd Steven | Buy | 9,103 | .41 | 3,777 |
| 2018-06-25 | Boyd Steven | Buy | 10,672 | .42 | 4,482 |
| 2018-06-22 | Boyd Steven | Buy | 14,520 | .42 | 6,069 |
| 2018-06-21 | Boyd Steven | Buy | 140 | .42 | 58 |
| 2018-06-20 | Boyd Steven | Buy | 3,702 | .42 | 1,562 |
| 2018-06-18 | Boyd Steven | Buy | 13,742 | .40 | 5,510 |
| 2018-06-14 | Boyd Steven | Buy | 29,103 | .38 | 11,175 |
| 2018-06-13 | Boyd Steven | Buy | 145,297 | .35 | 51,580 |
| 2018-06-12 | Boyd Steven | Buy | 156,895 | .38 | 60,247 |
| 2018-06-11 | Boyd Steven | Buy | 368,705 | .40 | 146,375 |
| 2018-01-22 | Boyd Steven | Buy | 100,000 | .48 | 47,800 |
| 2017-11-10 | Merton Robert C (Director) | Buy | 85,700 | 1.75 | 149,975 |
| 2017-03-27 | Ramos Anthony Alan (VP, Chief Accounting Officer) | Sale | 4,250 | 2.17 | 9,239 |
| 2017-03-15 | Smith Lawrence Russell (VP, Vaccine Research) | Sale | 875 | 2.31 | 2,021 |
| 2017-02-10 | Smith Lawrence Russell (VP, Vaccine Research) | Sale | 4,500 | 2.26 | 10,161 |
| 2017-02-01 | Samant Vijay B (President & CEO) | Sale | 3,750 | 2.16 | 8,088 |
| 2017-01-11 | Smith Lawrence Russell (VP, Vaccine Research) | Sale | 54 | 2.48 | 133 |
| 2017-01-10 | Samant Vijay B (President & CEO) | Sale | 5,763 | 2.45 | 14,113 |
| 2016-12-22 | Merton Robert C (Director) | Sale | 2,000 | 2.26 | 4,520 |
| 2016-12-21 | Merton Robert C (Director) | Sale | 2,000 | 2.22 | 4,440 |
| 2016-12-20 | Merton Robert C (Director) | Sale | 2,000 | 2.22 | 4,440 |
| 2016-12-19 | Merton Robert C (Director) | Sale | 2,327 | 2.21 | 5,142 |
| 2016-12-13 | Samant Vijay B (President & CEO) | Sale | 4,649 | 2.40 | 11,171 |
| 2016-12-12 | Douglas R Gordon (Director) | Sale | 10,078 | 2.39 | 24,106 |
| 2016-12-12 | Samant Vijay B (President & CEO) | Sale | 11,050 | 2.39 | 26,420 |
| 2016-12-05 | Lyons Gary A (Director) | Sale | 7,078 | 2.30 | 16,251 |
| 2016-10-11 | Smith Lawrence Russell (VP, Vaccine Research) | Sale | 54 | 3.05 | 164 |
| 2016-07-11 | Smith Lawrence Russell (VP, Vaccine Research) | Sale | 54 | 4.46 | 240 |
| 2016-06-14 | Merton Robert C (Director) | Buy | 4,100 | 4.41 | 18,068 |
| 2016-06-13 | Merton Robert C (Director) | Buy | 4,900 | 4.29 | 21,030 |
| 2016-06-09 | Samant Vijay B (President & CEO) | Buy | 15,700 | 4.72 | 74,151 |
| 2016-06-06 | Douglas R Gordon (Director) | Buy | 10,078 | 4.41 | 44,443 |
| 2016-06-03 | Lyons Gary A (Director) | Buy | 7,078 | 4.39 | 31,086 |
| 2016-03-15 | Smith Lawrence Russell (VP, Vaccine Research) | Sale | 8,750 | .41 | 3,587 |
| 2016-02-19 | Ramos Anthony Alan (VP, Chief Accounting Officer) | Sale | 7,500 | .33 | 2,475 |
| 2016-01-25 | Ramos Anthony Alan (VP, Chief Accounting Officer) | Sale | 193 | .35 | 67 |
| 2016-01-12 | Samant Vijay B (President & CEO) | Sale | 11,202 | .35 | 3,909 |
| 2016-01-11 | Smith Lawrence Russell (VP, Vaccine Research) | Sale | 974 | .36 | 350 |
| 2016-01-11 | Samant Vijay B (President & CEO) | Sale | 48,535 | .35 | 16,841 |
| 2016-01-07 | Samant Vijay B (President & CEO) | Sale | 75,000 | .36 | 27,075 |
| 2015-10-23 | Ramos Anthony Alan (VP, Chief Accounting Officer) | Sale | 193 | .39 | 75 |
| 2015-10-12 | Smith Lawrence Russell (VP, Vaccine Research) | Sale | 974 | .43 | 414 |
| 2015-10-12 | Samant Vijay B (President & CEO) | Sale | 4,738 | .41 | 1,961 |
| 2015-07-23 | Ramos Anthony Alan (VP, Chief Accounting Officer) | Sale | 194 | .62 | 120 |
| 2015-07-13 | Smith Lawrence Russell (VP, Vaccine Research) | Sale | 974 | .70 | 679 |
| 2015-07-13 | Bilinsky Igor (Sr VP, Corporate Development) | Sale | 1,258 | .70 | 879 |
| 2015-07-13 | Samant Vijay B (President & CEO) | Sale | 4,737 | .70 | 3,311 |
| 2015-04-23 | Ramos Anthony Alan (VP, Chief Accounting Officer) | Sale | 193 | 1.01 | 194 |
| 2015-04-13 | Smith Lawrence Russell (VP, Vaccine Research) | Sale | 974 | .93 | 909 |
| 2015-04-13 | Bilinsky Igor (Sr VP, Corporate Development) | Sale | 1,257 | .93 | 1,172 |
| 2015-04-13 | Samant Vijay B (President & CEO) | Sale | 4,738 | .93 | 4,411 |
| 2015-03-30 | Samant Vijay B (President & CEO) | Sale | 55,000 | .91 | 50,160 |
| 2015-01-21 | Ramos Anthony Alan (VP, Chief Accounting Officer) | Sale | 428 | 1.09 | 466 |
| 2015-01-13 | Samant Vijay B (President & CEO) | Sale | 4,737 | 1.12 | 5,310 |
| 2015-01-12 | Smith Lawrence Russell (VP, Vaccine Research) | Sale | 1,912 | 1.16 | 2,210 |
| 2015-01-12 | Bilinsky Igor (Sr VP, Corporate Development) | Sale | 1,335 | 1.16 | 1,543 |
| 2014-10-21 | Ramos Anthony Alan (VP, Chief Accounting Officer) | Sale | 428 | 1.18 | 505 |
| 2014-10-13 | Smith Lawrence Russell (VP, Vaccine Research) | Sale | 1,912 | 1.08 | 2,066 |
| 2014-10-13 | Bilinsky Igor (Sr VP, Corporate Development) | Sale | 1,335 | 1.08 | 1,445 |
| 2014-10-13 | Samant Vijay B (President & CEO) | Sale | 4,738 | 1.13 | 5,353 |
| 2014-08-26 | Smith Lawrence Russell (VP, Vaccine Research) | Sale | 12,500 | 1.25 | 15,675 |
| 2014-08-26 | Bilinsky Igor (Senior VP, Corporate Dev't) | Sale | 12,500 | 1.25 | 15,675 |
| 2014-08-26 | Ramos Anthony Alan (VP, Chief Accounting Officer) | Sale | 12,500 | 1.25 | 15,675 |
| 2014-07-21 | Ramos Anthony Alan (VP, Chief Accounting Officer) | Sale | 428 | 1.29 | 552 |
| 2014-07-14 | Samant Vijay B (President & CEO) | Sale | 4,737 | 1.17 | 5,542 |
| 2014-07-11 | Smith Lawrence Russell (VP, Vaccine Research) | Sale | 1,912 | 1.16 | 2,225 |
| 2014-07-11 | Bilinsky Igor (Senior VP, Corporate Dev't) | Sale | 1,335 | 1.16 | 1,553 |
Insider trading activities including stock purchases, stock sales, and option exercises of VICL listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Fresh Tracks Therapeutics, Inc. (symbol VICL, CIK number 819050) see the Securities and Exchange Commission (SEC) website.